Rocca Maria A, Preziosa Paolo, Barkhof Frederik, Brownlee Wallace, Calabrese Massimiliano, De Stefano Nicola, Granziera Cristina, Ropele Stefan, Toosy Ahmed T, Vidal-Jordana Àngela, Di Filippo Massimiliano, Filippi Massimo
Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Lancet Reg Health Eur. 2024 Aug 22;44:100978. doi: 10.1016/j.lanepe.2024.100978. eCollection 2024 Sep.
In the majority of cases, multiple sclerosis (MS) is characterized by reversible episodes of neurological dysfunction, often followed by irreversible clinical disability. Accurate diagnostic criteria and prognostic markers are critical to enable early diagnosis and correctly identify patients with MS at increased risk of disease progression. The 2017 McDonald diagnostic criteria, which include magnetic resonance imaging (MRI) as a fundamental paraclinical tool, show high sensitivity and accuracy for the diagnosis of MS allowing early diagnosis and treatment. However, their inappropriate application, especially in the context of atypical clinical presentations, may increase the risk of misdiagnosis. To further improve the diagnostic process, novel imaging markers are emerging, but rigorous validation and standardization is still needed before they can be incorporated into clinical practice. This Series article discusses the current role of MRI in the diagnosis and prognosis of MS, while examining promising MRI markers, which could serve as reliable predictors of subsequent disease progression, helping to optimize the management of individual patients with MS. We also explore the potential of new technologies, such as artificial intelligence and automated quantification tools, to support clinicians in the management of patients. Yet, to ensure consistency and improvement in the use of MRI in MS diagnosis and patient follow-up, it is essential that standardized brain and spinal cord MRI protocols are applied, and that interpretation of results is performed by qualified (neuro)radiologists in all countries.
在大多数情况下,多发性硬化症(MS)的特征是神经功能障碍的可逆性发作,随后往往会出现不可逆的临床残疾。准确的诊断标准和预后标志物对于实现早期诊断以及正确识别疾病进展风险增加的MS患者至关重要。2017年麦克唐纳诊断标准将磁共振成像(MRI)作为基本的临床辅助工具,对MS诊断具有高敏感性和准确性,能够实现早期诊断和治疗。然而,其应用不当,尤其是在非典型临床表现的情况下,可能会增加误诊风险。为了进一步改进诊断过程,新的成像标志物不断涌现,但在将其纳入临床实践之前,仍需要严格的验证和标准化。本系列文章讨论了MRI在MS诊断和预后中的当前作用,同时研究了有前景的MRI标志物,这些标志物可作为后续疾病进展的可靠预测指标,有助于优化MS个体患者的管理。我们还探讨了人工智能和自动定量工具等新技术在支持临床医生管理患者方面的潜力。然而,为确保在MS诊断和患者随访中使用MRI的一致性和改进,必须应用标准化的脑和脊髓MRI方案,并且所有国家都应由合格的(神经)放射科医生进行结果解读。